Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded Warrants and Warrants
Summary
6105 or by email at syndicate@svbsecurities.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.89bio is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases. The companys lead candidate, pegozafermin, is in clinical development for the treatment of non-alcoholic steatohepatitis ( ) and severe hypertriglyceridemia (SHTG). Words such as may, might, will, objective, intend, should, could, can, would, expect, believe, design, estimate, predict, potential, anticipate, goal, opportunity, develop, plan or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. 89bio expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.